“We believe our achievements from this past quarter, including capacity ... Centered in the US, Legend is building an end-to-end cell therapy company by expanding its leadership to maximize ...

CARVYKTI ® net trade sales of approximately $334 million and $963 million for the fourth quarter and full ... Centered in the US, Legend is building an end-to-end cell therapy company by ...

SOMERSET, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported its first quarter 2025 unaudited ...

We use Adjusted Net Loss and Adjusted Net Loss per Share (which we sometimes refer to as “Adjusted EPS” “ANL per Share”) as performance metrics. Adjusted Net Loss and ANL per share are not ...

(Legend Biotech), a global leader in cell therapy, today reported its first quarter 2025 unaudited financial results and key corporate highlights. “CARVYKTI, underpinned by its continued strong ...